CRDF Crosses Above Average Analyst Target
December 01, 2020 at 08:15 AM EST
In recent trading, shares of Cardiff Oncology Inc (CRDF) have crossed above the average analyst 12-month target price of $22.25, changing hands for $24.71/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..